Allogeneic red blood cell(RBC)transfusion is commonly performed in medical practice because of its efficacy and low-risk level.However,pre-transfusion tests are susceptible to monoclonal antibody(mAb)interference.1 Cu...Allogeneic red blood cell(RBC)transfusion is commonly performed in medical practice because of its efficacy and low-risk level.However,pre-transfusion tests are susceptible to monoclonal antibody(mAb)interference.1 Currently,mAb therapies are being developed to treat many diseases,such as cancer.However,certain mAbs,such as anti-CD38mAb and anti-CD47mAb,can bind to RBC membranes;this binding interferes with pre-transfusion tests.2 CD47 has gained considerable attention in recent years because of its potential as a therapeutic target for hematologic malignancies and solid tumors.3 The binding of anti-CD47mAb to RBCs may lead to false-positive results in pan-agglutination tests and cause delays and risks in establishing compatible RBCs for transfusion.展开更多
文摘Allogeneic red blood cell(RBC)transfusion is commonly performed in medical practice because of its efficacy and low-risk level.However,pre-transfusion tests are susceptible to monoclonal antibody(mAb)interference.1 Currently,mAb therapies are being developed to treat many diseases,such as cancer.However,certain mAbs,such as anti-CD38mAb and anti-CD47mAb,can bind to RBC membranes;this binding interferes with pre-transfusion tests.2 CD47 has gained considerable attention in recent years because of its potential as a therapeutic target for hematologic malignancies and solid tumors.3 The binding of anti-CD47mAb to RBCs may lead to false-positive results in pan-agglutination tests and cause delays and risks in establishing compatible RBCs for transfusion.
